A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).
Public ClinicalTrials.gov record NCT04188379. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia
Study identification
- NCT ID
- NCT04188379
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- argenx
- Industry
- Enrollment
- 131 participants
Conditions and interventions
Conditions
Interventions
- efgartigimod Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2019
- Primary completion
- Feb 2, 2022
- Completion
- Feb 2, 2022
- Last update posted
- Mar 12, 2025
2019 – 2022
United States locations
- U.S. sites
- 9
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site 0010038 | Tucson | Arizona | 85711 | — |
| Investigator Site 0010045 | Washington D.C. | District of Columbia | 20007 | — |
| Investigator Site 0010034 | Jacksonville | Florida | 32204 | — |
| Investigator site 0010037 | Ocala | Florida | 34474 | — |
| Investigator Site 0010042 | Iowa City | Iowa | 52242 | — |
| Investigator Site 0010046 | Greenville | North Carolina | 27834 | — |
| Investigator Site 0010049 | Cleveland | Ohio | 44106 | — |
| Investigator Site 0010040 | Columbus | Ohio | 44106 | — |
| Investigator Site 0010041 | Philadelphia | Pennsylvania | 19104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 112 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04188379, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 12, 2025 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04188379 live on ClinicalTrials.gov.